Tempest Therapeutics Inc. (TPST)
$0.95
$-0.04
(-4.11%)
As on 09-Sep-2026 11:26EDT
Market cap
$17 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
22.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-9.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-4.6
-
Face value
--
-
Shares outstanding
16,539,767
10 Years Aggregate
CFO
$-356.43 Mln
EBITDA
$-429.85 Mln
Net Profit
$-442.67 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
| -67.0 | 3.2 | -25.5 | -91.3 | -43.8 | -65.2 | -63.2 |
|
BSE Sensex
| -11.7 | -4.8 | 1.7 | -7.5 | 3.9 | 5.1 | 9.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
| -73.5 | -80.8 | 282.6 | -78.2 | -83.6 | -68.2 | -15.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Tempest Therapeutics (TPST)
|
0.9 | 17.0 | 0.0 | -40.5 | -- | -- | -- | 22.9 |
| 84.7 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 263.9 | 17,746.8 | 1,054.4 | 755.9 | 5.7 | -- | 20.9 | 10.5 | |
| 73.6 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 57.4 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 107.7 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 341.1 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 116.4 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 541.3 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 583.7 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 |
Shareholding Pattern
View DetailsAbout Tempest Therapeutics (TPST)
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated... receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California. Read more
-
CEO, President & Director
Mr. Stephen R. Brady J.D., LLM
-
CEO, President & Director
Mr. Stephen R. Brady J.D., LLM
-
Headquarters
Brisbane, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Tempest Therapeutics (TPST)
What is the current share price of Tempest Therapeutics Inc (TPST) Today?
The share price of Tempest Therapeutics Inc (TPST) is $0.95 (NASDAQ) as of 09-Sep-2026 11:26 EDT. Tempest Therapeutics Inc (TPST) has given a return of -43.79% in the last 3 years.
What is the current PB & PE ratio of Tempest Therapeutics Inc (TPST)?
Since, TTM earnings of Tempest Therapeutics Inc (TPST) is negative, P/E ratio is not available.
The P/B ratio of Tempest Therapeutics Inc (TPST) is 22.94 times as on 04-Sep-2026, a 330 premium to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.45 |
1.79 |
2024 |
-0.56 |
1.22 |
2023 |
-3.21 |
3.54 |
2022 |
-0.34 |
0.67 |
2021 |
-1.25 |
0.98 |
What is the 52 Week High and Low of Tempest Therapeutics Inc (TPST)?
The 52-week high and low of Tempest Therapeutics Inc (TPST) are Rs 12.23 and Rs 0.84 as of 09-Sep-2026.
What is the market cap of Tempest Therapeutics Inc (TPST)?
Tempest Therapeutics Inc (TPST) has a market capitalisation of $ 17 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Tempest Therapeutics Inc (TPST)?
Before investing in Tempest Therapeutics Inc (TPST), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.